The global Digital Therapeutics (DTx) market is currently undergoing a seismic shift, evolving from a niche technological concept into a cornerstone of modern evidence-based medicine. Valued at over USD 5 billion in 2023 and projected to grow at a CAGR of 25% through 2030, DTx represents a new category of healthcare that utilizes high-quality software programs to prevent, manage, or treat medical disorders.
Unlike general wellness apps, DTx products are clinically validated and often require regulatory approval (such as FDA 510(k) or CE Mark). From chronic insomnia and Type 2 diabetes to cardiovascular health and mental wellbeing, digital therapeutics are bridging the gap between clinical visits and daily patient lives.
North America: Leading in adoption due to favorable reimbursement policies and high smartphone penetration.
Europe: Rapidly expanding through initiatives like Germany's DiGA (Digital Healthcare Act).
Asia-Pacific: The fastest-growing region, driven by aging populations in Japan and China's digital transformation.
True digital therapy often requires a "closed-loop" system where real-time data informs software interventions. This is where medical-grade smart wearables come into play. For instance, a Smart Ring monitoring heart rate variability (HRV) can provide the necessary data points for an AI-driven stress management platform to suggest immediate breathing exercises or cognitive behavioral therapy (CBT) modules.
As a leading exporter, we provide the hardware foundation—the sensors and biometric collectors—that top-tier DTx software companies rely on to deliver accurate therapeutic outcomes.
Predictive analytics are now standard. DTx solutions can predict a hypoglycemic event or a depressive episode days before they occur by analyzing subtle changes in physiological data.
Global procurement is shifting toward "Remote Patient Monitoring" (RPM) kits that allow chronic patients to receive intensive therapy in the comfort of their homes.
DTx is no longer standalone; it is being integrated into virtual care platforms, providing doctors with a 24/7 view of patient progress between consultations.
Met Health: Innovating Smart Wearables with Love and Purpose
Founded in 2015, Met Health has become a leading manufacturer specializing in smart wearable devices. With over a decade of expertise in research and development, production, and management, we focus on delivering innovative solutions in senior health management, disease monitoring, and personal safety.
Our state-of-the-art production facility in Shenzhen is equipped with advanced production lines and precision equipment, ensuring high-quality manufacturing standards. As an ISO9001-certified company, we maintain stringent quality control throughout the production process.
In the realm of metabolic digital therapeutics, data precision is non-negotiable. Our 8-Electrode Body Fat Scales provide a comprehensive clinical picture, measuring segmental fat and muscle mass. For a DTx provider focusing on diabetes reversal or weight management, this level of granularity allows for hyper-personalized nutritional and exercise prescriptions.
By exporting these precision instruments to over 50 countries, Met Health acts as the physical backbone for the world's most innovative health tech exporters.
Focus on fall detection and early dementia screening through gait analysis and sleep monitoring wearables.
High demand for integrated glucose monitoring and BMI tracking to combat rising diabetes and obesity rates.
Wearables that track physiological stress markers (cortisol indicators, HR, Sleep) to supplement digital CBT platforms.
Over a decade of experience in R&D and manufacturing specialized wearable solutions for senior health and safety.
ISO9001-certified Shenzhen facility with state-of-the-art production lines and stringent reliability testing.
Tailored OEM/ODM services to deliver personalized solutions that meet the specific software integration needs of our clients.
Years R&D Experience
Monthly Production
Exporting Countries
9001 Certified
Met Health
